-
Mashup Score: 2
On November 2, 2022, it was announced that the European Commission had granted approval to zanubrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior line of anti-CD20-based therapy.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Zanubrutinib receives positive CHMP opinion for the treatment of adult patients with MZL - 2 year(s) ago
On September 19, 2022, it was announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for the Bruton’s tyrosine kinase inhibitor zanubrutinib for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 The @EMA_News issues a positive CHMP opinion for zanubrutinib in adult patients with R/R #MZL: https://t.co/XSOPDhjBna #lymsm #mednews
-
-
Mashup Score: 2NewsDetails - 2 year(s) ago
Contact Rachel Darwin, Senior Manager, Public Relations darwin@nccn.org, 267-622-6624 NCCN’s New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer …
Source: NCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The NEW NCCN Guidelines for Patients: Marginal Zone Lymphoma (MZL) just posted! Access now: https://t.co/4cauNCEgba #NCCNFoundation #MZL https://t.co/00lID38AU6
-
-
Mashup Score: 0Current Treatments in Marginal Zone Lymphoma - 2 year(s) ago
This review provides an updated analysis of the literature and discusses the authors’ approach to the diagnosis and treatment of patients with marginal zone lymphoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This review provides an updated analysis of the literature and discusses the authors' approach to the diagnosis and treatment of patients with marginal zone lymphoma. #MZL | @JuanAlderuccio https://t.co/jacPTU7Ftn
-
-
Mashup Score: 1
The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma. #FL #MZL #lymsm #FDA https://t.co/JvEXqmrflr
-
-
Mashup Score: 5international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma - 2 year(s) ago
Key Points. Bendamustine with rituximab is a highly effective frontline therapy in extranodal marginal zone lymphoma across all extranodal sitesBendamustine wit
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🗝️KEY POINT ▪️Bendamustine +rituximab is highly effective frontline therapy in extranodal #MZL across all extranodal sites and overcame known poor prognosis features 👉 https://t.co/Q9InLOrdGo 👈 #lymsm #lymphoma
-
-
Mashup Score: 4international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma - 2 year(s) ago
Key Points. Bendamustine with rituximab is a highly effective frontline therapy in extranodal marginal zone lymphoma across all extranodal sitesBendamustine wit
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🗝️KEY POINTS ▪️Bendamustine with rituximab is a highly effective frontline therapy in extranodal #MZL across all extranodal sites ▪️Bendamustine with rituximab overcomes known poor prognosis features in extranodal #MZL 👉 https://t.co/Q9InLOrdGo 👈 #lymphoma #lymsm https://t.co/kLh1d5vHfE
-
-
Mashup Score: 0When is CAR-T a good option for patients with follicular and marginal zone lymphomas? - 2 year(s) ago
During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We asked, When is CAR-T a good option for patients with follicular and marginal zone lymphomas?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 During #CART22, the Lymphoma Hub spoke with @gilles_salles, @MSKCancerCenter. We asked, When is CAR-T a good option for patients with follicular and marginal zone #lymphoma? 👉 https://t.co/uVXKPoPKtP 👈 #lymsm #FL #MZL https://t.co/GIarP2APaO
-
-
Mashup Score: 4
On January 25, 2022, the new drug application for parsaclisib to treat relapsed/refractory mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma was withdrawn.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 N E W S 🚨 Parsaclisib new drug application withdrawn for R/R #MCL,#MZL, and follicular #lymphoma. The decision was made after discourse with the @US_FDA about the additional time needed for confirmatory studies 👉 https://t.co/EYqTTFrdwS 👈 #lymsm https://t.co/Wh2SJw4CUc
-
-
Mashup Score: 0CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage - PubMed - 2 year(s) ago
Conventionally, mantle cell lymphoma (MCL) is an aggressive CD5-positive B-cell malignancy with poor prognosis and limited survival. However, a small subset of patients presents with indolent disease and can be managed on a ‘watch and wait’ approach. CD5-negative MCL has recently been recognized as …
Source: PubMedCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🗝️KEY POINTS ▪️In #MZL median overall survival exceeds 14 years ▪️It's independent of favorable prognostic markers such as leukemic non-nodal disease, absence of SOX11, and low Ki-67 👉 https://t.co/0yvPhpwvhM 👈 #lymsm #lymphoma
-
🚨 NEWS 🚨 Zanubrutinib has been granted EC approval for the treatment of patients with R/R #MZL. Read more here 👉 https://t.co/odUtAv1sBu. #mednews #lymsm https://t.co/UYyG0itoBS